StrategicFunding Sanavia Oncology is a NYC-based biotech focused on immunotherapies with a small team and modest revenue, indicating an opportunity to tailor early-stage partnerships, grant-supported projects, or equity investments that align with their growth stage.

AcademicLeveraged The team’s background from top-tier institutions suggests a receptiveness to collaboration with universities, CROs, and research partners for joint R&D programs, licensing negotiations, and sponsored research arrangements.

AIDrivenAdvances Their proprietary platform that combines immunology with AI to identify epitopes and select antibodies presents a sales angle for AI-enabled drug discovery tools, data collaboration platforms, or enhanced analytical services.

ClinicalPotential Targeting first-in-class, cancer-specific epitopes in drug-resistant tumors positions Sanavia as a candidate for strategic partnerships with larger pharma for co-development, licensing, or milestone-based collaborations.

GrowthOpportunities With revenue in the 1–10 million range and growth-focused messaging, there’s a opportunity to offer grant programs, pilot collaborations, contract research, or technology licensing to accelerate their pipeline and expand go-to-market activities.